| Literature DB >> 27411385 |
Tânia Curiao1,2, Emmanuela Marchi3, Denis Grandgirard4, Ricardo León-Sampedro5,6, Carlo Viti3, Stephen L Leib4, Fernando Baquero5,6,7, Marco R Oggioni8, José Luis Martinez7,9, Teresa M Coque10,11,12.
Abstract
BACKGROUND: Biocides and antibiotics are used to eradicate or prevent the growth of microbial species on surfaces (occasionally on catheters), or infected sites, either in combination or sequentially, raising concerns about the development of co-resistance to both antimicrobial types. The effect of such compounds on Salmonella enterica, a major food-borne and zoonotic pathogen, has been analysed in different studies, but only few works evaluated its biological cost, and the overall effects at the genomic and transcriptomic levels associated with diverse phenotypes resulting from biocide exposure, which was the aim of this work.Entities:
Keywords: Antimicrobial susceptibility; Biocide resistance; Collateral sensitivity; Transcriptomics; WGS
Mesh:
Substances:
Year: 2016 PMID: 27411385 PMCID: PMC4943003 DOI: 10.1186/s12864-016-2778-z
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Susceptibility profiles of Salmonella mutants respect to SL1344 parental strain
| N.° | Pre-conditioning agent | Biocide Phenotype | Biocide MIC (mg/L) | Antibiotic MIC (mg/L) | Mutant designation | Fitness Cost (%) | Frequency of mutation | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRI | BKC | CHX | AMP | CAZ | CIP | ERY | GEN | CLO | TET | ||||||
| - |
|
|
|
|
|
|
|
|
|
|
| ||||
| 1 | NE | TRIR/BKCR/CHXR | 2 | 32 | 32 | 1.5 | 0.38 | 0.047 | 32-48 | 1.5 | 3 | 2 |
| 11 | >1.25E-07 |
| 2 | NE | 0.12 | 32 | 32 | 1 | 0.25 | 0.032 | 32 | 1.0 | 4 | 4 |
| 34 | 2.92E-09 | |
| 3 | BKC | 0.12 | 32 | 32 | 2 | 0.38 | 0.023 | 32 | 1.5 | 3 | 4 | BKC/AMP | - | 2.50E-09 | |
| 4 | CHX | 0.12 | 32 | 32 | 1 | 0.5 | 0.032 | 48 | 1.5 | 2 | 2 |
| - | 1.67E-09 | |
| 5 | BKC | TRIR/BKCR | 0.12 | 32 | 16 | 2 | 0.38 | 0.032 | 48 | 0.5 | 4 | 4 | BKC/BKC3 | - | 2.50E-09 |
| 6 | CIP | BKCR | 0.06 | 32 | 16 | 1.5 | 0.5 | 0.032 | 24 | 1.5 | 2-3 | 1.5 | CIP/TRI1 | More fit | <1.50E-05 |
| 7 | TRI | 0.06 | 32 | 16 | 2 | 0.5 | 0.032 | 32 | 1.5 | 3 | 2-3 |
| 31 | 1.50E-09 | |
| 8 | NE | BKCR/CHXR/TRIHS | 0.03 | 32 | 32 | 2 | 0.38 | 0.032 | 32-48 | 1 | 4 | 4 | NE/BKC2 | - | 1.25E-07 |
| 9 | NE | 0.03 | 32 | 32 | 1.5 | 0.75 | 0.047 | 24 | 1.5 | 3 | 1.5 |
| more fit | 2.08E-11 | |
| 10 | TRI | 0.015 | 32 | 32 | 1.5 | 0.5 | 0.032 | 24 | 1.5 | 2 | 1.5 | TRI/AMP | - | 3.06E-09 | |
| 11 | BKC | 0.015 | 64 | 32 | 2 | 0.38 | 0.023 | 32 | 1 | 3 | 4 | BKC/CHX2 | - | 1.67E-08 | |
| 12 | CIP | TRIHS/CHXHS | 0.03 | 16 | 8 | 2 | 0.38 | 0.032 | 32 | 2 | 4 | 3 | CIP/CHX1 | - | <2.50E-06 |
| 13 | BKC | TRIHS | 0.015 | 16 | 16 | 1 | 0.38 | 0.023 | 64 | 1.5 | 3 | 1.5 | BKC/CIP | - | 1.50E-09 |
| 14 | CHX | 0.015 | 16 | 16 | 2 | 0.38 | 0.023 | 32-48 | 0.75 | 3 | 4 |
| 17 | 4.17E-09 | |
NE: non-exposed, - Not done
In the designation of mutants, numbers 1-3 refer to the concentration of compounds in plates as follows: 1- 32 mg/L, 2- 64 mg/L and 3-128 mg/L
Mutants CIP/TRI1 and CIP/CHX1 classified as more fit than SL1344 exhibited -17 % and -21 %, respectively
WGS was performed in the underlined mutants
Techniques carried out for a representative subset of mutants
| Mutant n° | Mutant name | Biolog (Table | WGS (Table | Gene expression (Fig. |
|---|---|---|---|---|
| 1 | NE/TRI1 | Yes | Yes | Yes |
| 2 | NE/CHX2 | No | Yes | Yes |
| 4 | CHX/BKC3 | Yes | Yes | Yes |
| 7 | TRI/BKC3 | Yes | Yes | Yes |
| 9 | NE/BKC3 | Yes | Yes | Yes |
| 10 | TRI/AMP | Yes | No | No |
| 11 | BKC/CHX2 | Yes | No | No |
| 14 | CHX/AMP | Yes | Yes | Yes |
Yes and No denotes whether the technique was performed or not
Antimicrobial susceptibility determined by BIOLOG for Salmonella enterica mutants in comparison to the parental strain
| TRIR/BKCR/CHXR | BKCR | BKCR/CHXR/TRIHS | TRIHS | |||||
|---|---|---|---|---|---|---|---|---|
| Chemicals | Inhibitor Family | NE/TRI1 | CHX/BKC3 | TRI/BKC3 | NE/BKC3 | TRI/AMP | BKC/CHX2 | CHX/AMP |
| ANTIBIOTICS | ||||||||
| Neomycin | aminoglycosides | R | R | R | R | R | R | S |
| Paromomycin | S | S | S | S | ||||
| Sisomicin | S | S | R | R | S | R | R | |
| Chloramphenicol | amphenicols | S | S | S | ||||
| Thiamphenicol | R | R | R | R | R | |||
| Cefazolin | cephalosporins | R | ||||||
| Ceftriaxone | S | |||||||
| Amoxicillin | lactams | S | R | S | S | S | R | R |
| Aztreonam | S | S | S | |||||
| Carbenicillin | S | S | S | |||||
| Carbenicillin (II) | R | |||||||
| Phleomycin | DNA oxidants | R | ||||||
| Cinoxacin | DNA topoisomerases inhibitors | S | S | S | S | S | R | |
| Ciprofloxacin | R | R | R | R | ||||
| Enoxacin | R | S | S | S | S | S | R | |
| Nalidixic acid | R | S | S | R | S | S | R | |
| Novobiocin | S | |||||||
| Ofloxacin | S | S | S | S | S | |||
| Pipemidic acid | R | |||||||
| Hydroxyurea | folate antagonists | R | S | R | S | R | R | S |
| Trimethoprim | R | R | R | R | R | |||
| Troleandomycin | macrolides | R | R | R | ||||
| Rifampicin | RNA polymerase inhibitors | S | ||||||
| Penimepicycline | tetracyclines | S | S | S | R | S | ||
| Tetracycline | S | |||||||
| NON-ANTIBIOTICS | ||||||||
| 1-Hydroxypyridine-2-thione | chelators | S | S | S | ||||
| 5,7-Dichloro-8-OHquinoline | S | S | S | |||||
| 5-Chloro-7-iodo-8-OHquinoline | S | R | S | R | S | S | ||
| 8-Hydroxyquinoline | R | R | R | R | ||||
| Fusaric acid | S | S | S | S | ||||
| 2-Phenylphenol | DNA intercalators | R | ||||||
| Chloroxylenol | Fungicides | R | ||||||
| Patulin | R | R | R | R | ||||
| Colistin | Membrane active agents | S | S | S | S | S | S | R |
| Polymyxin B | S | S | S | S | ||||
| Polymyxin B (II) | R | |||||||
| Poly-L-lysine | S | S | S | S | S | S | S | |
| Alexidine | S | S | ||||||
| Ornidazole | oxidizing agents | S | S | S | ||||
| 1-Chloro-2,4-dinitrobenzene | S | S | R | S | R | R | ||
| Atropine | other drugs | S | S | |||||
| Pridinol | R | R | R | R | R | |||
| Propranolol | S | S | S | S | S | S | ||
| Chlorpromazine | S | S | S | S | S | S | ||
| Benzethonium chloride | QACs | S | S | S | R | S | S | R |
| Cetylpyridinium chloride | S | |||||||
| Sodium azide | respiration, uncoupler | S | ||||||
| Thioridazine | S | S | S | |||||
| Potassium chromate | toxic anions | S | S | S | S | S | R | |
| Potassium tellurite (II) | S | R | R | R | S | S | ||
| Sodium metaborate | S | S | S | S | S | S | S | |
| Sodium tungstate | R | |||||||
| Sodium periodate | R | R | ||||||
| Antimony(III) chloride | toxic cations | R | R | R | R | R | ||
| Cadmium chloride | R | R | ||||||
| Thallium(I) acetate | R | R | ||||||
| D,L-Methionine hydroxamate | other inhibitors | S | S | S | S | S | S | S |
| Phenyl-methylsulfonyl-fluoride | S | S | S | S | S | S | ||
| D-Serine | R | |||||||
| 6-Mercaptopurine | S | S | R | |||||
| Compound 48/80 | S | S | ||||||
Blank cells indicate that no variation in the susceptibility were found in comparison to the parental strain
Mutations identified in sequenced mutants
| TRIRCHXRBKCR | BKCR | TRIHSCHXRBKCR | TRIHS | |||||
|---|---|---|---|---|---|---|---|---|
| Function | Gene | NE/TRI1 | NE/CHX2 | CHX/BKC3 | TRI/BKC3 | NE/BKC3 | CHX/AMP | |
| Amino acid/peptide transport/metabolism |
| G → T/A74A | ||||||
| Energy production/amino acid metabolism |
| T → A/L317Q | ||||||
| Lipid metabolism |
| G → A/G93S | ||||||
| Membrane/transport |
| T → A/V168E | ||||||
| Replication |
| T → G/P772P | A → T/Q780H | A → T/Q793H | ||||
| Surface structures |
| T → C/F61L | ||||||
|
| T → G/E128D | |||||||
| Virulence |
| Deletion:408 bp | Deletion:331 bp | Deletion:293 bp | ||||
| Intergenic | -/- i | T → A | ||||||
|
| A → C | A → C | ||||||
|
| C → T | |||||||
| Unknown |
| C → G/T321T | ||||||
Description of gene products: a Asparagine synthetase A, b Ubiquinone biosynthesis protein; c Enoyl-acyl carrier protein reductase (NADH); d Membrane transporter TolA protein; e Cell division protein FtsK; f Hypothetical outer membrane protein; g Motility protein B; h Hypothetical surface-exposed virulence protein; i Intergenic region between Glutamyl-t-RNA synthetase (459 bp)/(359 bp) Xanthosin operon transcriptional regulator; j Intergenic region between Phosphoribosylaminoimidezolecarboxamide fosmyltransferase and IMP cyclohydrolase/- (16S rRNA); k tdc operon transcriptional activator/Hypothetical surface-exposed virulence protein; l Hypothetical membrane protein of Major Facilitator Superfamily (transporter)
Fig. 1Volcano plots of genes showing altered expression after exposure to biocides in the six mutants analyzed. Log2 fold changes and their corresponding p-values of all genes in the microarray were considered to build the Volcano plot. Genes up-regulated (>1.5 fold change, p< 0.05) are depicted in red box. Genes down regulated (>1.5 fold change, p < 0.05) appear in blue boxes. Genes that did not show a significantly modified pattern are represented in grey dots and the yellow dots depict the genes found in both SAM and LIMMA outputs for each mutant
Fig. 2Heat map of the genes with altered expression in different mutants
Fig. 3Volcano plots of genes showing altered expression in both natural isolates and mutants. Log2 fold changes and their corresponding p-values of all genes in the microarray were considered to build the Volcano plot. Genes up-regulated (>1.5 fold change, p < 0.05) are depicted in red box. Genes down regulated (>1.5 fold change, p < 0.05) appear in blue boxes. Genes that did not show a significantly modified pattern are represented in grey dots.
Fig. 4Heat map of the common genes with altered expression of natural isolates and mutants